Stock Comparison

NTLA vs PRME

Intellia Therapeutics Inc vs Prime Medicine Inc

The Verdict

NTLA takes this one.

Winner

NTLA

Intellia Therapeutics Inc

9.1

out of 10

Hidden Gem

PRME

Prime Medicine Inc

3.0

out of 10

Risk Trap

Head-to-Head

$1.8B

Market Cap

$641M

-4.4

P/E Ratio

N/A

-597.0%

Profit Margin

-4917.6%

-57.3%

Return on Equity

-188.8%

0.2

Debt-to-Equity

N/A

Aggressive

Overall Risk

Aggressive

9.1

DVR Score

3.0

The Deep Dive

NTLA9.1/10

Intellia Therapeutics continues to demonstrate strong execution in its pioneering gene-editing pipeline. The positive Phase 3 data for lonvo-z in HAE and the initiation of its rolling BLA submission, targeting a 1H 2027 launch, are transformative. The FDA's lifting of clinical holds on nex-z trials further de-risks its broader platform. While the company remains unprofitable, its Q1 2026 earnings ...

Full NTLA Analysis

PRME3.0/10

Prime Medicine's Prime Editing technology still represents transformative potential in genetic diseases, addressing a vast TAM with strong IP, justifying a high growth potential score. However, this upside is severely constrained by persistent and critical financial challenges. The Q1 2026 earnings report (May 7, 2026) confirmed a revenue miss at $0.86M and an EPS miss at -$0.28, alongside a signi...

Full PRME Analysis

Want More Comparisons?

Run any stock through our deep value analyzer.

Analyze Any Stock →

Not Financial Advice

This comparison is for educational purposes only. We are not financial advisors. Always do your own research and consult a qualified advisor before investing.